Latest "Frontier Capital" News Stories

22:26 EDT 25th March 2019 | BioPortfolio

Here are the most relevant search results for "Frontier Capital" found in our extensive news archives from over 250 global news sources.

More Information about Frontier Capital on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Frontier Capital for you to read. Along with our medical data and news we also list Frontier Capital Clinical Trials, which are updated daily. BioPortfolio also has a large database of Frontier Capital Companies for you to search.

Showing "Frontier Capital" News Articles 1–25 of 3,400+

Monday 25th March 2019

Monarch Medical Technologies Appoints Bruce Lisanti as New President and Chief Executive Officer

Monarch Medical Technologies, the leader in precision insulin dosing technology for optimized glycemic management, today announced that Bruce Lisanti has been named president and chief executive officer, effective immediately. Lisanti succeeds Linda Beneze who retired from her role as Monarch CEO. “On behalf of the board, we first would l...

VenatoRx Pharmaceuticals to Present Orally Bioavailable Broad-Spectrum Beta-Lactamase Inhibitor for Superbugs at ACS National Meeting

First Time Disclosure of Clinical Candidates Presentation Scheduled for April 3, 2019 at 10:35am ET VenatoRx Pharmaceuticals announced that its President and CEO,

PreveCeutical Announces Default Judgment Against Essos Corporate Services Inc. and Detona Capital Corp.

PreveCeutical Medical Inc. (CSE:PREV, OTC:PRVCF, FSE:18H) (the "Company" or "PreveCeutical"), announces that it has obtained a default judgement against each of Essos Corporate Services Inc. ("Essos") and Detona Capital Corp. ("Detona") in connection with a Supreme Court of British Columbia action (the "Action"). The post PreveCeutical Announces Default Judgment Against Essos Corporate Services In...

Charles G. Berg Joins Turn-Key Health Board of Directors: Executive Leader at DaVita Medical Group, WellCare, UnitedHealth and Oxford

Turn-Key Health (Turn-Key), an Enclara Healthcare company, serving health plans, provider organizations and their members who experience a serious or advanced illness, welcomes Charles “Chuck” Berg, a veteran healthcare executive who has served in various leadership roles throughout the industry, to its board of directors. Currently, he is on the ...

Bone Biologics Receives Human Research Ethics Committee (HREC) Approval for the First Center of a Multicenter Pilot Clinical Trial to Evaluate NB1 (NELL-1/DBX®) in Australia

Bone Biologics Corp. (OTCQB:BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, today has announced that it received Human Research Ethics Committee (HREC) approval on March 20, 2019, for the first center of a multicenter pilot clinical trial to evaluate NB1 (NELL-1/DBX®) in 30 patients in Australia. The ...

Flare Capital Partners Appoints Parth Desai as Senior Associate

Expands Investment Team to Reinvent the Business of Healthcare Flare Capital Partners, a leading healthcare technology venture capital firm, today announced the addition of healthcare technology investor and experienced policy professional Parth Desai as a Senior Associate. “Parth has dedicated his

Bioasis Technologies Inc. Announces Warrant Extension

BIOASIS TECHNOLOGIES INC. (“Bioasis” or the “Company”) (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, incl...

Appili Therapeutics Announces Closing of $3.6 Million Special Warrant Private Placement and Filing of Preliminary Prospectus

NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES. Appili Therapeutics Inc. ("Appili" or the "Company") is pleased to announce the closing of its private placement offering (the "Brokered Offering") of special warrants (the "Special Warrants") for aggregate gross proceed...

Enterprise Therapeutics strengthens leadership team, appoints Amit D. Munshi as Non-Executive Chairman

Appointment brings significant commercial pharma experience as Enterprise Therapeutics’ two lead respiratory programmes are progressed towards the clinic Brighton, UK, 25 March 2019: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, tod...

NetScientific soars as it sells stakes in Vortex Biosciences and Wanda for £150,000

The group said after the close on 22 March that it would use the proceeds of the sale towards its ongoing working capital requirements

PreveCeutical gets default judgement in part of civil claim

Preveceutical said it had received a default judgment against Essos Corporate Services Inc and Detona Capital

Fuse Medical Reports Full Year 2018 Financial Results with Record Earnings

Fuse Medical, Inc., (OTCPINK: FZMD), an emerging manufacturer and distributor of medical devices for the orthopedic and spine marketplace, announced record earnings for the fiscal year ended December 31, 2018. Fuse filed its annual report on Form 10-K with the Securities and Exchange Commission on Thursday, March 21, 2019. 2018 Financial Highlight...

Synerkine Pharma Raises EUR3.3 Million in Series A Financing

Proceeds to build pipeline of novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain Synerkine Pharma B.V., which develops fusion proteins for the treatment of chronic pain, announced today that it successfully closed a EUR 3.3 million Series A financing from Thuja Capital, an undisclosed private investor, and the ...

Thermo Fisher Scientific to buy viral vector CDMO Brammer Bio for $1.7bn

Owned by Ampersand Capital Partners, Brammer Bio is engaged in the clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy. The post Thermo Fisher Scientific to buy viral vector CDMO Brammer Bio for $1.7bn appeared first on Pharmaceutical Business review.

NetScientific sells stakes in Vortex Biosciences and Wanda for £150,000

The group said after the close on 22 March that it would use the proceeds of the sale towards its ongoing working capital requirements

Friday 22nd March 2019

What Tilray Thinks About The 'Farming Business' And Why The Company May Need To Raise More Capital Soon

Now Cashed Up, Biopharma to Advance Cholesterol-Lowering Therapy

Source: Streetwise Reports   03/23/2019 A ROTH Capital Partners report reviewed this New Jersey firm's plans for its lead asset.In a March 21 research note, ROTH Capital Partners analyst Jerry Isaacson reported that Matinas BioPharma Holdings Inc. (MTNB:OTC.MKTS) is "positioned for success" following its equity raise, "executed under favorable terms." Expected gross pr...

Navidea Biopharmaceuticals Announces Stock Purchase Agreement; Other Business Updates

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced execution of a Stock Purchase Agreement (the “Purchase Agreement”) with an existing investor, John K. Scott, Jr. (the “Investor”), pursuant to ...

At #CGDay19, panelists say the ability of cell and #genetherapy companies to raise capital hinges on how well they address #manufacturing and address medical needs beyond #Cancer: 

At #CGDay19, panelists say the ability of cell and #genetherapy companies to raise capital hinges on how well they address #manufacturing and address medical needs beyond #Cancer: 

Weekly Policy Update: Colorado State Budget and Forecast, Plus CBSA Voices Concerns on Drug Pricing Legislation

Last week the non-partisan Legislative Council published the forecast for the economy and state government revenue through FY 2019-20. The forecast showed that while the economy will continue to grow in 2019 and 2020, it is expected to slow as a result of global economic slowdown and stronger headwinds from tightening labor markets. It also indicated that revenue projections for this yea...

Imago BioSciences raises $40mm in Series B round

Imago BioSciences Inc. (developing treatments for proliferative bone marrow diseases) raised $40mm in its Series B round. Ome...

China’s Birth Rates Fall in Several Regions in 2018: China Daily

(Reuters) – China’s birth rate in several regions, including the capital Beijing, fell again in 2018, the official China Daily said on Friday, despite government efforts to encourage couples to have more children. Alarmed by the rapid aging of its … Read More

Address Manufacturing and Look Beyond Cancer, Panel Advises Cell and Gene Therapy Companies

The ability of cell and gene therapy companies to raise capital this year will hinge on their ability to address the manufacturing of their products as well as address medical needs beyond cancer, a panel of three investors and an industry executive agreed yesterday. Speaking at the Alliance for Regenerative Medicine (ARM)’s Cell & Gene […] The post Address Manufacturing and Look Beyon...

MorphoSys: Aufstockung der Netto-Leerverkaufsposition von Capital Fund Management

Martinsried ( - Leerverkäufer Capital Fund Management SA erhöht Netto-Leerverkaufsposition in MorphoSys-Aktien moderat: Die Leerverkäufer von Capital Fund Management SA haben ihr...

MedMen Announces US$250 Million Investment From Gotham Green Partners

MedMen Enterprises Inc. (CSE:MMEN) (OTCQX:MMNFF) (FSE: A2JM6N) (“MedMen” or the “Company”), is pleased to announce that it has signed a binding term sheet for a senior secured convertible credit facility of up to US$250,000,000 (the “Facility”) from funds managed by Gotham Green Partners (“GGP” or the “Investor”), an investor in the glo...

Quick Search


News Quicklinks